Unit dosage of apadenoson

Abstract

The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging.

1 . (canceled) 
     
     
         2 . A method of chemically inducing stress and diagnosing myocardial perfusion abnormalities in a mammal, comprising:
 (a) selecting a unit dose of Apadenoson between about 76-175 ug for the mammal wherein the mammal's weight falls within a specified weight range and the unit dose comprises: Apadenoson and a pharmaceutically acceptable carrier;   (b) administering the unit dose to the mammal; and   (c) performing a technique to detect the presence of coronary artery stenoses in the mammal, to assess the severity of coronary artery stenoses in the mammal, or a combination thereof, so as to diagnose myocardial perfusion abnormalities in the mammal.   
     
     
         3 . The method of  claim 2 , wherein the unit dose further contains an effective amount of β-hydroxypropyl-cyclodextrin (HP-β-CD). 
     
     
         4 . The method of  claim 3 , wherein the amount of HP-β-CD is about 0.1-10% w/v of the final formulation. 
     
     
         5 . The method of  claim 4 , wherein the amount of HP-β-CD is 1% w/v. 
     
     
         6 . The method of  claim 2 , wherein the dose of Apadenoson is 76 μg. 
     
     
         7 . The method of  claim 2 , wherein the dose of Apadenoson is 110 μg. 
     
     
         8 . The method of  claim 2 , wherein the dose of Apadenoson is 115 μg. 
     
     
         9 . The method of  claim 2 , wherein the dose of Apadenoson is 120 μg. 
     
     
         10 . The method of  claim 2 , wherein the dose of Apadenoson is 125 μg. 
     
     
         11 . The method of  claim 2 , wherein the dose of Apadenoson is 130 μg. 
     
     
         12 . The method of  claim 2 , wherein the dose of Apadenoson is 140 μg. 
     
     
         13 . The method of  claim 2 , wherein the unit dose is 1 mL in volume. 
     
     
         14 . The method of  claim 2 , wherein the unit dose is 2 mL in volume. 
     
     
         15 . The method of  claim 2 , wherein the unit dose is 3 mL in volume. 
     
     
         16 . The method of  claim 2 , wherein the unit dose is 4 mL in volume. 
     
     
         17 . The method of  claim 2 , wherein the unit dose is 5 mL in volume. 
     
     
         18 . The method of  claim 2 , wherein the dose of Apadenoson is selected on the basis of a single weight of Apadenoson being effective in previously tested mammals having a range of different weights. 
     
     
         19 . The method of  claim 2 , wherein the unit dose further contains sodium citrate buffer. 
     
     
         20 . The method of  claim 19 , wherein sodium citrate buffer is present in an amount to buffer the unit dose to pH selected from 4.6-5.0. 
     
     
         21 . The method of  claim 19 , wherein sodium citrate buffer is present in an amount to buffer the unit dose to pH 4.8.